Heart Rhythm
Volume 6, Issue 6 , Pages 776-783, June 2009

Aldosterone blockade attenuates development of an electrophysiological substrate associated with ventricular tachyarrhythmias in heart failure

  • Bruce S. Stambler, MD, FHRS

      Affiliations

    • University Hospitals Case Medical Center, Cleveland, Ohio
    • Corresponding Author InformationAddress reprint requests and correspondence: Dr. Bruce Stambler, University Hospitals Case Medical Center, 11100 Euclid Avenue, Cleveland, Ohio 44106
    • ,
  • Kenneth R. Laurita, PhD

      Affiliations

    • MetroHealth Campus, Case Western Reserve University, Cleveland, Ohio
    • ,
  • Sunil C. Shroff, MD

      Affiliations

    • University Hospitals Case Medical Center, Cleveland, Ohio
    • ,
  • Gregory Hoeker, BS

      Affiliations

    • MetroHealth Campus, Case Western Reserve University, Cleveland, Ohio
    • ,
  • Nichole L. Martovitz

      Affiliations

    • University Hospitals Case Medical Center, Cleveland, Ohio

Received 28 November 2008; accepted 2 February 2009. published online 13 February 2009.

Background

Aldosterone blockade reduces sudden cardiac death in heart failure, but the underlying mechanism is unclear.

Objective

This study's aim was to determine whether chronic eplerenone treatment protects against detrimental ventricular electrical remodeling and development of an arrhythmogenic substrate in a rapid ventricular pacing (RVP)–induced heart failure model.

Methods

Dogs were assigned randomly to oral placebo or eplerenone treatment and divided into 4 groups: 2 sham-operated (no RVP) and 2 RVP groups. After 5 weeks of no RVP or RVP along with concurrent placebo or eplerenone treatment, dogs underwent echocardiographic assessments of systolic function and chamber size and electrophysiologic measurements of ventricular repolarization, refractoriness, conduction, tachyarrhythmia inducibility, and myocardial activation delays after premature stimulation.

Results

Eplerenone failed to prevent left ventricular systolic dysfunction or chamber enlargement in RVP dogs. Eplerenone attenuated prolongation of ventricular repolarization and refractoriness, increases in dispersion of repolarization and refractoriness, fractionation of ventricular electrograms, and delays in myocardial activation after premature stimulation at short coupling intervals and improved arrhythmia vulnerability score in RVP dogs with heart failure. Ventricular tachyarrhythmia inducibility in heart failure dogs was predicted by activation delays after premature stimulation at short coupling intervals, which were prevented by eplerenone. Eplerenone did not alter electrophysiological parameters in no-RVP dogs without heart failure.

Conclusions

Eplerenone attenuates heart failure–related ventricular electrical remodeling and tachyarrhythmia vulnerability. Inhibition of myocardial activation delays during premature excitation may contribute to preventing development of an arrhythmogenic ventricular substrate in heart failure.

Keywords: Heart failure, Electrophysiology, Aldosterone, Tachyarrhythmias, Eplerenone, Sudden death, Electrogram

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Supported by research grants from Pfizer, Inc., and the American Heart Association Ohio Valley to Dr. Stambler.

PII: S1547-5271(09)00130-1

doi:10.1016/j.hrthm.2009.02.005

Heart Rhythm
Volume 6, Issue 6 , Pages 776-783, June 2009

Article Tools

* Image Usage & Resolution